Table 2 Dynamic contrast-enhanced magnetic resonance imaging assessment (n=37)

From: Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours

Parameter

Baseline

After the first cycle

Change v baseline

 
 

Median

95% CI

Median

95% CI

Median

95% CI

P -value

DCE-MRI assessment after the first treatment cycle (n=37)

 Ktrans (min−1)

0.15

0.13 to 0.19

0.09

0.07 to 0.12

−32%

−6% to −62%

0.02

 IAUGC (mM l−1s−1)

10.2

8.9 to 14.0

7.2

5.3 to 9.4

−26%

−8% to −47%

0.005

DCE-MRI assessment over time in patients with decreased values (n=28)

 Ktrans (min−1)

0.16

0.13 to 0.26

0.07

0.05 to 0.10

−59%

−43% to −65%

<0.0001

 IAUGC (mMl−1 s−1)

11.7

9.2 to 17.8

5.7

4.6 to 8.1

−47%

−31% to −60%

<0.0001

  1. Abbreviations: CI=confidence interval; DCE-MRI=dynamic contrast-enhanced magnetic resonance imaging; IAUGC=initial area under concentration agent–time curve.
  2. Changes from baseline in Ktrans and IAUGC after the first treatment cycle and over time. Thirty-seven patients had only one post-baseline assessment and 28 patients more than one post-baseline assessment.
Back to article page